"Tranquil Clinical Research (CRO and Phase I Unit) was created to ensure that the entire clinical trial, device, and drug development process is conducted with ethics and the patient in mind first and always. TCR has a first of its kind patient centric inpatient Phase I Unit strategically located near the largest medical center in the world and in the most diverse city in the US and surrounded by 14 university/college systems."

During the past decade, Tranquility Research conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tranquility Research" #1 sponsor was "Pfizer" with 3 trials, followed by "First Wave BioPharma, Inc." with 1 trials sponsored, "Goldfinch Bio, Inc." with 1 trials sponsored, "Navidea Biopharmaceuticals" with 1 trials sponsored and "Phanes Therapeutics" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tranquility Research" #1 collaborator was "Oncobay Clinical, Inc" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Tranquility Research" are "COVID-19" (3 trials), "Advanced Cancer" (1 trials), "Advanced Solid Tumor" (1 trials), "Breast Adenocarcinoma" (1 trials) and "Colo-rectal Cancer" (1 trials). Many other conditions were trialed in "Tranquility Research" in a lesser frequency.

Most popular intervention types in "Tranquility Research" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "PF-07321332" (3 trials), "Placebo" (3 trials), "Ritonavir" (3 trials), "Anti-PD-1 monoclonal antibody" (1 trials) and "GFB-887" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tranquility Research" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Tranquility Research". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tranquility Research, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tranquility Research, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".